CLN3 disease process: missense point mutations and protein depletion in vitro.

Although the CLN3 gene associated with the disease process in subjects with the juvenile form of neuronal ceroid lipofuscinosis was discovered in 1995, our knowledge of the physiological function of its gene product, CLN3 protein, is still incomplete. To gain more insight into the structural properties and function of CLN3 protein we studied at present: i) how the naturally occurring point mutations Arg334Cys and Leu101Pro affect the biological properties of CLN3 protein, and ii) whether depletion of CLN3 protein synthesis by using an antisense approach induces a distinct phenotype in cells of neuronal origin in vitro. Here we report that although both CLN3 mutant proteins are targeted to lysosomes, thus similar to wild-type CLN3 protein, they are devoid of the biological activity of wild-type CLN3 protein such as its effect on lysosomal pH or intracellular processing of amyloid-beta protein precursor and cathepsin D in vitro. The Leu101Pro mutation affected significantly the maturation and stability of CLN3 protein. The Arg334Cys mutation influenced mildly the maturation and turnover of CLN3 protein, but at the same time abolished the function of CLN3 protein in vitro, which suggests that the Arg334 may constitute a part of the active site of CLN3 protein. In addition, we show that depletion of CLN3 protein synthesis in human neuroblastoma cells in vitro induces outgrowth of long cellular processes and formation of cellular aggregates and affects the viability of these cells. This finding suggests that CLN3 protein is implicated in biological processes associated with the differentiation of cells of neuronal origin.

[1]  K. Wisniewski,et al.  CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. , 2000, Molecular genetics and metabolism.

[2]  B. Davidson,et al.  Batten disease: evaluation of CLN3 mutations on protein localization and function. , 2000, Human molecular genetics.

[3]  I. Järvelä,et al.  Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL) , 1999, Human molecular genetics.

[4]  T. Ferea,et al.  Action of BTN1, the yeast orthologue of the gene mutated in Batten disease , 1999, Nature Genetics.

[5]  R. Boustany,et al.  CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. , 1999, Molecular genetics and metabolism.

[6]  K. Wisniewski,et al.  Studies of membrane association of CLN3 protein. , 1999, Molecular genetics and metabolism.

[7]  K. Wisniewski,et al.  Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro. , 1999, Molecular genetics and metabolism.

[8]  K. Wisniewski,et al.  Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro. , 1999, Molecular genetics and metabolism.

[9]  G. Sutherland,et al.  The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. , 1999, Human molecular genetics.

[10]  P. Munroe,et al.  Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis , 1999, Neurology.

[11]  K. Wisniewski,et al.  Evidence for phosphorylation of CLN3 protein associated with Batten disease. , 1998, Biochemical and biophysical research communications.

[12]  M. Forgac.  Structure, function and regulation of the vacuolar (H+)‐ATPases , 1998, FEBS letters.

[13]  H. C. Choi,et al.  The subcellular location of the yeast Saccharomyces cerevisiae homologue of the protein defective in the juvenile form of Batten disease. , 1998, Biochemical and biophysical research communications.

[14]  F. Sherman,et al.  A yeast model for the study of Batten disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Brown,et al.  Molecular screening of Batten disease: identification of a missense mutation (E295K) in the CLN3 gene , 1998, Human Genetics.

[16]  Kobert S. Schwartz,et al.  Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis , 1998, Annals of neurology.

[17]  L. Peltonen,et al.  Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. , 1998, Human molecular genetics.

[18]  G. Johnson,et al.  Immunochemical localization of the Batten disease (CLN3) protein in retina. , 1997, Investigative ophthalmology & visual science.

[19]  T. Lerner,et al.  Spectrum of mutations in the Batten disease gene, CLN3. , 1997, American journal of human genetics.

[20]  R. Rubenstein,et al.  Expression studies of CLN3 protein. , 1997, Neuropediatrics.

[21]  J. Haines,et al.  Isolation of a novel gene underlying batten disease, CLN3 , 1995, Cell.

[22]  M. Haussler,et al.  Retinoic acid-induced differentiation of human neuroblastoma: a cell variant system showing two distinct responses. , 1986, Experimental cell biology.

[23]  T. Takano,et al.  Identification and characterization of a proton pump on lysosomes by fluorescein-isothiocyanate-dextran fluorescence. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B Poole,et al.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Stevenson.  R. Foster Kennedy, M.D., 1884–1952 , 1952, Neurology.